Comparative Pharmacology
Head-to-head clinical analysis: TESTODERM versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTODERM versus TESTOSTERONE CYPIONATE ESTRADIOL CYPIONATE.
TESTODERM vs TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy: binds to androgen receptors, activating gene transcription for protein synthesis and muscle growth.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
One to two 2.5 mg or 5 mg patches applied to clean, dry, intact skin of the back, abdomen, upper arms, or thighs once daily (approximately every 24 hours).
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 10-100 minutes for free testosterone in plasma; for total testosterone (including bound), the apparent half-life ranges from 2-4 hours after transdermal application, with significant interindividual variability.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates, <10% as unchanged testosterone); about 6% is excreted in feces via biliary elimination.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Category C
Category D/X
Androgen
Androgen